2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-10936
    S 18986 175340-20-2 ≥99.0%
    S 18986 is a selective, orally active, brain penetrant positive allosteric modulator of AMPA-type receptors. S 18986 shows cognitive enhancing properties in rodents. S 18986 activates the release of noradrenaline and acetylcholine in rat hippocampus and enhances rat memory in object-recognition tests.
    S 18986
  • HY-10937
    Farampator 211735-76-1 99.87%
    Farampator (CX-691;Org24448) is an AMPA receptor positive modulator.
    Farampator
  • HY-12332
    JW 642 1416133-89-5 99.90%
    JW 642 is a potent inhibitor of monoacylglycerol lipase (MAGL) that displays IC50 values of 7.
    JW 642
  • HY-12394
    Dothiepin 113-53-1 ≥98.0%
    Dothiepin (Dosulepin; Dothep) is an antidepressant agent with sedative/anxiolytic activity. Dothiepin is an inhibitor preferring of noradrenaline uptake than serotonin uptake. Dothiepin facilitates noradrenergic neurotransmission via inhibiting the neuronal uptake. Dothiepin is also an antagonist of histamine H1-receptor without cardiotoxicity. Dothiepin exhibits significant analgesic activity in psychogenic facial pain，idiopathic fibromyalgia syndrome or rheumatoid arthritis.
    Dothiepin
  • HY-12499
    (S)-Willardiine 21416-43-3 ≥98.0%
    (S)-Willardiine is a potent agonist of AMPA/kainate receptors with EC50 of 44.
    (S)-Willardiine
  • HY-12685
    Ceralifimod 891859-12-4 99.29%
    Ceralifimod (ONO-4641) is selective, high potent agonist for sphingosine 1-phosphate receptors 1 and 5, with EC50s of 27.3, 334 pM for human S1P receptor 1 and 5, respectively.
    Ceralifimod
  • HY-14196
    Toloxatone 29218-27-7 98.11%
    Toloxatone (MD 69276) is a reversible monoamine oxidase A (MAOA) inhibitor. Antidepressant.
    Toloxatone
  • HY-14264
    Cyamemazine 3546-03-0 ≥99.0%
    Cyamemazine is a neuroleptic agent that contains the phenothiazine chromophore. Cyamemazine is often used as an anxiolytic. Cyamemazine is a potent 5-HT3 (Ki of 12 nM), 5-HT2A (Ki = 1.5 nM) and 5-HT2C (Ki of 75 nM) receptors antagonist with antipsychotic activity.
    Cyamemazine
  • HY-15086
    Selfotel 110347-85-8 99.67%
    Selfotel (CGS 19755) is a selective and competitive antagonist at N-methyl-D-aspartate (NMDA)-preferring receptor. CGS 19755 inhibits the binding of [3H]-3-(2-carboxypiperazin-4-yl)propyl-1-phosphonic acid to NMDA-type receptors with an IC50 of 50 nM.
    Selfotel
  • HY-15208
    Clamikalant sodium 261717-22-0 ≥98.0%
    Clamikalant sodium (HMR 1098) is an ATP-sensitive potassium (KATP) channel blocker. Clamikalant sodium can be used for the research of arrhythmia.
    Clamikalant sodium
  • HY-15703
    QNZ46 1237744-13-6 99.46%
    QNZ46 is a highly selective noncompetitive NMDA receptor antagonist targeting GluN2C/D (IC50=3.9 μM), GluN1/GluN2C (IC50=7.1 μM), and GluN1/GluN2D (IC50=182 μM) subunits. QNZ46 inhibits glutamate-mediated calcium influx, thereby blocking excitotoxicity. QNZ46 is membrane permeable and can cross the blood-brain barrier, where it inhibits myelin damage and axonal degeneration.
    QNZ46
  • HY-15831
    L-838417-d9 1213669-91-0 99.71%
    L-838417-d9 is the deuterium labeled L-838417. L-838417 is a subtype-selective GABAA positive allosteric modulator, acting as a partial agonist at α2, α3 and α5 subtypes.
    L-838417-d9
  • HY-15885
    LY2119620 886047-22-9 99.74%
    LY2119620 is a high-affinity muscarinic M2/M4 receptor agonist.
    LY2119620
  • HY-16423
    Rapacuronium bromide 156137-99-4 ≥98.0%
    Rapacuronium bromide (Org 9487), a non-depolarizing neuromuscular blocker, is an allosteric modulator of muscarinic acetylcholine receptor (mAChR).
    Rapacuronium bromide
  • HY-16436
    Rolapitant hydrochloride hydrate 914462-92-3 98.25%
    Rolapitant hydrochloride hydrate (SCH619734 hydrochloride hydrate) is a potent, selective, long-acting and orally active neurokinin 1 (NK1) receptor antagonist with a Ki of 0.66 nM. Rolapitant hydrochloride hydrate does not interact with CYP3A4. Rolapitant hydrochloride hydrate shows potent anti-emetic activity in a ferret emesis model.
    Rolapitant hydrochloride hydrate
  • HY-16732
    Tradipitant 622370-35-8 99.66%
    Tradipitant (VLY-686) is a neurokinin-1 (NK-1) antagonist.
    Tradipitant
  • HY-16936
    JH-II-127 1700693-08-8 ≥98.0%
    JH-II-127 is an orally active, highly potent, selective and brain-permeable LRRK2 inhibitor, with IC50s of 6, 2 and 48 nM for wild-type LRRK2 and LRRK2-G2019S and mutant LRRK2-A2016T. JH-II-127 inhibits Ser935 phosphorylation in all tissues of mice, including the brain. JH-II-127 can be used in the study of parkinson's syndrome.
    JH-II-127
  • HY-17549
    Adrafinil 63547-13-7 99.85%
    Adrafinil (CRL-40028, Olmifon), prodrug of modafinil, is a mild central nervous system stimulant drug used to relieve excessive sleepiness and inattention, Adrafinil is believed to serve as an alpha-1 adrenoceptor agonist.
    Adrafinil
  • HY-19168
    Perzinfotel 144912-63-0 ≥99.0%
    Perzinfotel (EAA-090) is a potent, selective, and competitive NMDA receptor antagonist with neuroprotective effects. Perzinfotel (EAA-090) shows high affinity (IC50=30 nM) for the glutamate site.
    Perzinfotel
  • HY-19361
    L-826266 244101-03-9 ≥98.0%
    L-826266 is a selective and competitive EP3 receptor antagonist. L-826266 can be used for convulsive disorders research.
    L-826266
Cat. No. Product Name / Synonyms Application Reactivity